» Articles » PMID: 10960060

Prevention by Dexrazoxane of Down-regulation of Ryanodine Receptor Gene Expression in Anthracycline Cardiomyopathy in the Rat

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2000 Aug 26
PMID 10960060
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Anthracyclines can cause cumulative dose-related cardiotoxicity characterized by changes in Ca(2+) metabolism, including dysfunction of the sacroplasmic reticulum (SR) and decreased expression of Ca(2+)-handling proteins, such as the ryanodine receptor (RyR2). In this study, we examined the effect of dexrazoxane (ICRF-187), an iron chelator which prevents anthracycline cardiotoxicity, on RyR2 gene expression in rats treated chronically with daunorubicin. Daunorubicin (2.5 mg kg(-1) i.v. weekly for 6 weeks) produced cardiotoxicity as demonstrated by histopathologic changes. The ryanodine receptor/glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA ratio was decreased by 38+/-3% (P<0.02) compared to values in control rats. Dexrazoxane pre-treatment (50 mg kg(-1); 1 h prior to each daunorubicin injection) prevented the decrease in RyR2/GAPDH mRNA ratio and histopathologic lesions in daunorubicin-treated rats. This is the first report that a protective agent such as dexrazoxane can ameliorate the decreased expression of a specific gene involved in anthracycline-induced cardiotoxicity.

Citing Articles

Electrical Conduction System Remodeling in Streptozotocin-Induced Diabetes Mellitus Rat Heart.

Zhang Y, Wang Y, Yanni J, Qureshi M, Logantha S, Kassab S Front Physiol. 2019; 10:826.

PMID: 31338036 PMC: 6628866. DOI: 10.3389/fphys.2019.00826.


Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.

Kucerova D, Doka G, Kruzliak P, Turcekova K, Kmecova J, Brnoliakova Z Am J Transl Res. 2015; 7(7):1280-94.

PMID: 26328012 PMC: 4548320.


Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V Antioxid Redox Signal. 2012; 18(8):899-929.

PMID: 22794198 PMC: 3557437. DOI: 10.1089/ars.2012.4795.


Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

Kaiserova H, den Hartog G, Simunek T, Schroterova L, Kvasnickova E, Bast A Br J Pharmacol. 2006; 149(7):920-30.

PMID: 17031387 PMC: 2014688. DOI: 10.1038/sj.bjp.0706930.

References
1.
Young R, Ozols R, Myers C . The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-53. DOI: 10.1056/NEJM198107163050305. View

2.
Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View

3.
Villani F, Galimberti M, Monti E, Cova D, Lanza E, Favalli L . Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol. 1990; 102(2):292-9. DOI: 10.1016/0041-008x(90)90028-s. View

4.
Olson R, Mushlin P . Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990; 4(13):3076-86. View

5.
Yeung T, Jaenke R, Wilding D, Creighton A, Hopewell J . The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol. 1992; 30(1):58-64. DOI: 10.1007/BF00686486. View